Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French Society of Pediatric Oncology.

@article{Laithier2003ProgressionfreeSI,
  title={Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French Society of Pediatric Oncology.},
  author={V{\'e}ronique Laithier and J Grill and Marie-C{\'e}cile le Deley and M Ruchoux and D. Valteau Couanet and François Doz and Fabienne Pichon and Herv{\'e} Rubi{\'e} and Didier Frappaz and Jean-Paul Vannier and Annie Babin-Boilletot and Eric Sariban and Pascal B Chastagner and Michel Z{\'e}rah and M Raquin and Olivier Hartmann and Chantal Kalifa},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2003},
  volume={21 24},
  pages={4572-8}
}
PURPOSE To evaluate a strategy aimed at avoiding radiotherapy during first-line treatment of children with progressive optic pathway tumors (OPT), by exclusively administering multiagent chemotherapy during 16 months. PATIENTS AND METHODS Between 1990 and 1998, 85 children with progressive OPT were enrolled onto this multicenter nationwide trial. Chemotherapy alternating procarbazine plus carboplatin, etoposide plus cisplatin, and vincristine plus cyclophosphamide was given every 3 weeks. At… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Similar Papers

Loading similar papers…